复发性喉癌的经口激光显微手术:系统综述与Meta分析
本系统综述与Meta分析纳入复发性喉癌成人患者,评估挽救性经口激光显微手术(TLM)的肿瘤学结局。初次(放)化疗后行挽救性TLM者235例,1、3、5年汇总局部控制率分别为74.2%、53.9%、39.1%;初次激光治疗后行TLM者271例,对应局部控制率分别为72.2%、53.2%、40.4%。作者认为由经验丰富术者并按严格选择标准实施时,TLM是局部复发性喉癌的有价值治疗选择,需进一步研究制定基于分期的临床指南。
要点
- 初次(放)化疗后挽救性TLM者235例,5年汇总局部控制率39.1%、疾病特异性生存率58.9%。
- 初次激光治疗后TLM者271例,5年汇总局部控制率40.4%、疾病特异性生存率67.1%。
- 作者认为由经验丰富术者并按严格选择标准实施时,TLM是局部复发性喉癌的有价值治疗选择。
核心结论
- 由经验丰富术者并按严格患者选择标准实施时,TLM是局部复发性喉癌的有价值治疗选择。
- 需进一步开展研究以制定基于分期的临床指南。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE、Cochrane Library和Scopus数据库。
- 纳入英文原创研究,研究对象为复发性喉癌成人患者,评估TLM的肿瘤学结局。
- 采用无分布方法合并数据,以随机效应模型估计汇总局部控制、疾病特异性生存和总生存曲线。
- 初次(放)化疗后行挽救性TLM者235例,平均随访60.8个月(95%CI:32.7-88.9)。
- 初次激光治疗后行TLM者271例,平均随访70.9个月(95%CI:36.9-104.9)。
主要发现
- 初次(放)化疗后挽救性TLM者235例,1、3、5年汇总局部控制率分别为74.2%(95%CI:61.7-89.4)、53.9%(95%CI:38.5-75.3)、39.1%(95%CI:25.2-60.8)。
- 初次(放)化疗后挽救性TLM者235例,1、3、5年汇总疾病特异性生存率分别为88.4%(95%CI:82.0-95.3)、67.8%(95%CI:50.9-90.3)、58.9%(95%CI:42.7-81.1)。
- 初次激光治疗后行TLM者271例,1、3、5年汇总局部控制率分别为72.2%(95%CI:64.7-80.6)、53.2%(95%CI:42.2-66.9)、40.4%(95%CI:29.6-55.2)。
- 初次激光治疗后行TLM者271例,1、3、5年汇总疾病特异性生存率分别为92.1%(95%CI:85.5-99.1)、77.0%(95%CI:64.4-92.0)、67.1%(95%CI:51.6-87.3)。
临床怎么用
- 作者认为,由经验丰富术者并按严格患者选择标准实施时,TLM是局部复发性喉癌的有价值治疗选择。
- 作者提出,需进一步开展研究以制定基于分期的临床指南。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the oncological outcomes of salvage transoral laser microsurgery (TLM) in the treatment of patients suffering from recurrent laryngeal cancer. METHODS: PubMed/MEDLINE, Cochrane Library, and Scopus databases were searched. English language, original studies investigating oncological outcomes of TLM in adult patients with recurrent laryngeal cancer were included. Data were pooled using a distribution-free approach for estimating summary local control (LC), disease-specific survival (DSS), and overall survival (OS) curves with random effects. RESULTS: Two hundred and thirty-five patients underwent salvage TLM after primary (chemo)radiotherapy. The mean follow-up time was 60.8 months (95% CI: 32.7-88.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 74.2% (61.7-89.4), 53.9% (38.5-75.3), and 39.1% (25.2-60.8). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 88.4% (82.0-95.3), 67.8% (50.9-90.3), and 58.9% (42.7-81.1). Two hundred and seventy-one patients underwent TLM after primary laser treatment. The mean follow-up time was 70.9 months (95% CI: 36.9-104.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 72.2% (64.7-80.6), 53.2% (42.2-66.9), and 40.4% (29.6-55.2). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 92.1% (85.5-99.1), 77.0% (64.4-92.0), and 67.1% (51.6-87.3). CONCLUSIONS: TLM is a valuable treatment option for the management of locally recurrent laryngeal carcinoma if performed by experienced surgeons and following rigorous patients' selection criteria. Further studies should be conducted to define stage-based clinical guidelines. LEVEL OF EVIDENCE: NA Laryngoscope, 133:1425-1433, 2023.
引用
- Russo E, Costantino A, Veneroni MV, et al. Transoral Laser Microsurgery in Recurrent Laryngeal Cancer: A Systematic Review and Meta-analysis. Laryngoscope. 2022. PMID: 37158265. doi:10.1002/lary.30332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。